| Literature DB >> 31649506 |
Emmanouela Leandrou1, Evangelia Emmanouilidou1,2, Kostas Vekrellis1.
Abstract
Alpha-synuclein (α-syn) is biochemically and genetically linked to Parkinson's disease (PD) and other synucleinopathies. It is now widely accepted that α-syn can be released in the extracellular space, even though the mechanism of its release is still unclear. In addition, pathology-related aggregated species of α-syn have been shown to propagate between neurons in synaptically connected areas of the brain thereby assisting the spreading of pathology in healthy neighboring neuronal cells. In neurons, calcium channels are key signaling elements that modulate the release of bioactive molecules (hormones, proteins, and neurotransmitters) through calcium sensing. Such calcium sensing activity is determined by the distinct biophysical and pharmacological properties and the ability of calcium channels to interact with other modulatory proteins. Although the function of extracellular α-syn is currently unknown, previous work suggested the presence of a calcium-dependent mechanism for α-syn secretion both in vitro, in neuronal cells in culture, and also in vivo, in the context of a trans-neuronal network in brain. Mechanisms regulating extracellular α-syn levels may be of particular importance as they could represent novel therapeutic targets. We discuss here how calcium channel activity may contribute to α-syn aggregation and secretion as a pathway to disease progression in synucleinopathies.Entities:
Keywords: Parkinson’s and related diseases; alpha-synuclein; calcium; neurodegeneration; protein aggregation; secretion; voltage gated Ca2+ channel
Year: 2019 PMID: 31649506 PMCID: PMC6794345 DOI: 10.3389/fnmol.2019.00237
Source DB: PubMed Journal: Front Mol Neurosci ISSN: 1662-5099 Impact factor: 5.639
Voltage-gated calcium channel blockers and their effect on PD pathophysiology.
| N-type P/Q-type | ω-conotoxin ω-agatoxin | Sprague–Dawley rats | Decreased the dopamine release from striatal terminals | |
| R-type | SNX-482 | Sprague–Dawley rats | Decreased the somatodendritic DA release in SN | |
| T-type | Ni2+ mifebradil | STN slices + Wistar rats | Reduced the burst activity in STN neurons and improved the locomotor deficits in 6-OHDA lesioned rats | |
| ML218 | iPSCs derived from dopaminergic neurons of PARK-2 patients | Ameliorated the effect of rotenone treatment by rescuing the neuronal apoptotic phenotype | ||
| N-type | ω-conotoxin | Rat primary cortical neurons | Diminished the elevation of intracellular calcium and dopamine release that was triggered after extracellular α-synuclein application | |
| L-type N-type | Nifedipine ω-conotoxin | SH-SY5Y cells | Diminished the elevation of intracellular calcium that was observed when extracellular α-synuclein was applied to the cells | |
| Isradipine | Adult brain slices + C57BL/6 mice | Reversed the rotenone and MPTP-induced TH-loss and motor deficits | ||
| Nimodipine | Primary dopaminergic neurons | Reduced the increased levels of cytosolic dopamine that are observed after L-DOPA administration | ||
| Isradipine | C57B1/6 mito-roGFP transgenic mice | Reduced the mitochondrial oxidant stress in SNc dopaminergic neurons | ||
| Isradipine | C57BL/6 mice | Increased the survival of SNc dopaminergic cells after 6-OHDA- induced degeneration | ||
| L-type | Isradipine Nimodipine | Primary dopaminergic neurons | Prevented the MPP+-induced intracellular calcium elevation in SN but not in VTA. | |
| Isradipine | 6-OHDA-treated mice | Failed to achieve neuroprotection of SNc neurons, due to low selectivity for Cav1.3 VGCCs | ||
| Isradipine | TH-mito-roGFP transgenic mice | Decreased mitochondrial oxidant stress was achieved by reducing Ca2+ oscillations in SNc | ||
| Isradipine | Ventral mesencephalic primary neurons | Reversed the clustering of a-synuclein positive vesicles and α-synuclein aggregation that is observed after dopamine administration |
FIGURE 1Interplay of α-syn and Ca2+. Elevation of intracellular Ca2+ levels through voltage-gated calcium channels (VGCCs) may lead to aggregation of α-syn via indirect interactions with calcium binding proteins such as Calmodulin, or via direct binding of Ca2+ to α-syn that leads to exposure of NAC domain (A), elevation of intracellular amounts of α-syn may lead to VGCCs opening and calcium influx that results in increased formation of reactive oxygen species (ROS) and neurodegeneration (B). It still remains unclear whether elevation of intracellular Ca2+ is the cause or the result of α-syn aggregation which promotes the release and propagation of α-syn -the release is accomplished either through exosomes or through other proposed secretory mechanisms (C).